Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics

被引:49
作者
Becquemont, L. [1 ]
Neuvonen, M.
Verstuyft, C.
Jaillon, P.
Letierce, A.
Neuvonen, P. J.
Funck-Brentano, C.
机构
[1] Hop Bicetre, AP HP, Serv Genet Mol & Pharmacogenet, Le Kremlin Bicetre, France
[2] Univ Paris 11, Dept Pharmacol, Unite Rech Clin, Le Kremlin Bicetre, France
[3] Univ Paris 11, Dept Pharmacol, Ctr Invest Biol, Le Kremlin Bicetre, France
[4] Univ Paris Sud, Dept Pharmacol, Fac Med, Le Kremlin Bicetre, France
[5] Univ Helsinki, Dept Clin Pharmacol, FIN-00014 Helsinki, Finland
[6] Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland
[7] Hop St Antoine, Serv Pharmacol, F-75571 Paris, France
[8] Univ Paris 06, Fac Med, Dept Pharmacol, Paris, France
[9] Univ Paris 06, Dept Pharmacol, Ctr Invest Clin, Paris, France
[10] INSERM, Paris, France
关键词
D O I
10.1038/sj.clpt.6100098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to determine the influence of amiodarone on the pharmacokinetics of simvastatin and pravastatin in humans. This was a prospective, crossover, randomized, open-label study performed in 12 healthy volunteers comparing the pharmacokinetics of a single oral dose of simvastatin ( 40 mg) or pravastatin ( 40 mg) taken alone and after 3 days of amiodarone ( 400 mg/day). Amiodarone increased simvastatin acid AUC ( area under the plasma concentration-time curve)(0-24h), peak plasma concentration ( C-max), and t(1/2) by 73% ( P = 0.02), 100% ( P = 0.02), and 48% ( P = 0.06), respectively, whereas it did not significantly alter pravastatin pharmacokinetics. Point estimates and 90% confidence intervals for simvastatin acid, simvastatin lactone, and pravastatin AUC(0-24) h were 154% ( 109-216%), 155% ( 109-227%), and 86% ( 63-118%), respectively. If amiodarone and a statin have to be simultaneously prescribed, pravastatin should be preferred to simvastatin in order to avoid a drug interaction.
引用
收藏
页码:679 / 684
页数:6
相关论文
共 34 条
  • [21] PHARMACOKINETIC DRUG-INTERACTIONS WITH AMIODARONE
    LESKO, LJ
    [J]. CLINICAL PHARMACOKINETICS, 1989, 17 (02) : 130 - 140
  • [22] Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin
    Lilja, JJ
    Kivistö, KT
    Neuvonen, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (04) : 384 - 390
  • [23] Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
    Lilja, JJ
    Kivistö, KT
    Neuvonen, PJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) : 118 - 127
  • [24] Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin
    Lilja, JJ
    Neuvonen, M
    Neuvonen, PJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (01) : 56 - 60
  • [25] Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
    Mwinyi, J
    Johne, A
    Bauer, S
    Roots, I
    Gerloff, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) : 415 - 421
  • [26] Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
    Neuvonen, PJ
    Kantola, T
    Kivistö, KT
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (03) : 332 - 341
  • [27] High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
    Niemi, M
    Schaeffeler, E
    Lang, T
    Fromm, MF
    Neuvonen, M
    Kyrklund, C
    Backman, JT
    Kerb, R
    Schwab, M
    Neuvonen, PJ
    Eichelbaum, M
    Kivistö, KT
    [J]. PHARMACOGENETICS, 2004, 14 (07): : 429 - 440
  • [28] SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
    Niemi, Mikko
    Pasanen, Marja K.
    Neuvonen, Pertti J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (04) : 356 - 366
  • [29] Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes:: Consequences for pravastatin pharmacokinetics
    Nishizato, Y
    Ieiri, I
    Suzuki, H
    Kimura, M
    Kawabata, K
    Hirota, T
    Takane, H
    Irie, S
    Kusuhara, H
    Urasaki, Y
    Urae, A
    Higuchi, S
    Otsubo, K
    Sugiyama, Y
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) : 554 - 565
  • [30] Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities:: Prediction of in vivo drug interactions
    Ohyama, K
    Nakajima, M
    Suzuki, M
    Shimada, N
    Yamazaki, H
    Yokoi, T
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (03) : 244 - 253